Pharming Group (PHAR) Fundamental Analysis: Revenue, Earnings & Valuation

3.52 / 10

Netural

Fundamental analysis rates PHAR neutral (3.5/10). Inventory turnover (0.75) and cost‑of‑sales (12.1%) are strong, but long‑term debt to working capital (0.58) and interest coverage (1.80) are weak, indicating liquidity strain. Overall, the balance‑sheet picture is challenging.

Analysis Checks(9/10)

Revenue-MV

Value-0.45

Score2/3

Weight22.24%

1M Return4.88%

Total operating revenue (YoY growth rate %)

Value26.56

Score2/3

Weight0.48%

1M Return0.13%

Inventory turnover ratio

Value0.75

Score3/3

Weight-3.44%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value51.96

Score2/3

Weight1.36%

1M Return0.36%

PB-ROE

Value1.35

Score2/3

Weight32.71%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.58

Score1/3

Weight-2.36%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value1.80

Score2/3

Weight-4.06%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value26.56

Score2/3

Weight0.19%

1M Return0.05%

Cost of sales ratio (%)

Value12.10

Score3/3

Weight1.02%

1M Return0.26%

Asset-MV

Value-0.55

Score2/3

Weight51.86%

1M Return11.12%

Is PHAR undervalued or overvalued?

PHAR scores 3.52/10 on fundamentals and holds a Fair valuation at present. Backed by its 1.14% ROE, 0.67% net margin, 408.30 P/E ratio, 4.20 P/B ratio, and 122.22% earnings growth, these metrics solidify its Netural investment rating.